Global Submucosal Injections Market Overview
Submucosal Injections Market Size was valued at USD 1.1 Billion in 2022. The Submucosal injections market industry is projected to grow from USD 1.16 Billion in 2023 to USD 1.89 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.21% during the forecast period (2023 - 2032). Increasing prevalence of chronic diseases and advancements in drug delivery technologies are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Submucosal Injections Market Trends
- Increasing prevalence of chronic diseases is driving the market growth
The market for submucosal injections is expanding as a result of the rising incidence of chronic disorders. Conditions including diabetes, cancer, Crohn's disease, and ulcerative colitis are examples of chronic diseases, which are frequently characterized by their protracted duration and gradual advancement. These illnesses put a significant strain on healthcare systems around the world, necessitating the development of more specialized and effective treatment alternatives including submucosal injections.
Complex and erratic symptoms are frequently present in chronic disorders. Submucosal injections make it possible to personalize treatment plans by letting medical professionals change dosages and frequency to suit the needs of each patient. This degree of personalization has the potential to improve patient outcomes and disease management, which is critical in the setting of chronic illnesses.
The preference for submucosal injections is also influenced by the possibility that patients with chronic diseases have particular difficulties that render other delivery techniques ineffective. For instance, esophageal or throat strictures or inflammation in people with gastrointestinal problems may impede their ability to absorb medication or make it difficult for them to swallow oral drugs. Submucosal injections provide a dependable and direct route for drug administration in these circumstances, ensuring that the treatment reaches its intended target.
Chronic diseases have a significant financial cost that cannot be understated. These ailments frequently necessitate repeated hospital stays, surgeries, and the usage of long-term medications, incurring high medical expenses. By enhancing treatment outcomes and lowering the need for invasive surgical procedures, submucosal injections can assist to reduce these expenses. Additionally, they might result in fewer complications and shorter hospital stays, which would ultimately result in cost savings for both patients and healthcare systems.
The prevalence of chronic diseases is predicted to increase further as the world's population continues to age. The likelihood of having chronic disorders increases with life expectancy because age is a major risk factor for many of these illnesses. With their capacity to deliver targeted and effective treatment, submucosal injections are becoming more and more important in the management of chronic diseases in an older population. Thus, driving the submucosal injections market revenue.
Submucosal Injections Market Segment Insights
Submucosal Injections Type of Agent Insights
The submucosal injections market segmentation, based on type of agent, includes eleview and ORISE gel, normal saline, sextrose water, hydroxyethyl starch, hydroxypropyl methylcellulose, succinylated gelatin, hyaluronic acid and fibrinogen mixture. The eleview and ORISE gel segment dominated the market in 2022. A submucosal injectable substance called Eleview is utilized during endoscopic operations as a submucosal fluid cushion. In order to increase the visibility and security of endoscopic treatments, it must be able to establish and maintain a stable submucosal fluid cushion. Eleview is a potent submucosal drug that is needed as the demand for endoscopic treatments for diagnostic and therapeutic purposes rises.
Submucosal Injections Application Insights
The submucosal injections market segmentation, based on application, includes colorectal cancer, gastic cancer and esophageal cancer. The colorectal cancer category generated the most income in 2022. Surgery for colorectal cancer can be invasive and has a higher risk of complications as well as a lengthier recovery period. Submucosal injections offer a minimally invasive therapeutic option, eliminating the need for complex surgical procedures and the hazards involved.
Submucosal Injections End User Insights
The submucosal injections market segmentation, based on end user, includes hospitals, surgical centers and others. The hospitals segment dominated the market in 2022. Hospitals are leading the way in treating patients with a variety of illnesses, such as cancer, gastrointestinal problems, and chronic diseases. To provide the best possible patient outcomes, these illnesses frequently need for accurate and efficient drug delivery techniques. Hospitals can use submucosal injections to administer medications and treatments directly to the afflicted tissues, improving the effectiveness of treatment.
Figure 1: Submucosal Injections Market, by End User, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Submucosal Injections Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Submucosal Injections Market dominated this market in 2022 (45.80%). North America is a hub for medical research and development, with numerous pharmaceutical and biotechnology companies based in the United States and Canada. This fosters innovation in drug delivery methods, driving the growth of the submucosal injections market. Further, the U.S. Submucosal injections market held the largest market share, and the Canada Submucosal injections market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: SUBMUCOSAL INJECTIONS MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Submucosal injections market accounts for the second-largest market share. A developed pharmaceutical sector exists in Europe and makes R&D investments. The market for submucosal injections is expanding because of this industry's interest in cutting-edge drug delivery systems. Further, the German Submucosal injections market held the largest market share, and the UK Submucosal injections market was the fastest growing market in the European region.
The Asia-Pacific Submucosal Injections Market is expected to grow at the fastest CAGR from 2023 to 2032. A large chunk of the world's population resides in the Asia Pacific region. The demand for efficient treatment options like submucosal injections is driven by the sheer quantity of people with chronic diseases and other medical disorders. Moreover, China’s submucosal injections market held the largest market share, and the Indian Submucosal injections market was the fastest growing market in the Asia-Pacific region.
Submucosal injections Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the submucosal injections market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, submucosal injections industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the submucosal injections industry to benefit clients and increase the market sector. In recent years, the submucosal injections industry has offered some of the most significant advantages to medicine. Major players in the Submucosal injections market, including Seikagaku Corp., Ovesco Endoscopy AG, GI Supply, Cosmo Pharmaceuticals, Boston Scientific, The Standard, Micro-Tech Endoscopy, ENDOCLOT PLUS, INC. and others, are attempting to increase market demand by investing in research and development operations.
Devices are developed, manufactured, and sold by Boston Scientific Corp. (Boston Scientific) for a range of interventional medical specialties. The company sells products in a variety of medical specialties, including electrophysiology, gastroenterology, gastrointestinal surgery, female pelvic medicine, gynecology, interventional cardiology, interventional radiology, neurological surgery, orthopedic surgery, pain management, pulmonology, urology, and vascular surgery. Boston Scientific offers services to hospitals, clinics, outpatient facilities, and medical offices all around the world. The company has manufacturing sites in the US, Ireland, Costa Rica, Brazil, Malaysia, and Puerto Rico. Both directly and through a network of distributors and dealers, it sells goods across Europe, the Middle East, Africa, Asia Pacific, and the Americas. Boston Scientific's corporate offices are in the US city of Marlborough, Massachusetts.
COSMOS Pharmaceutical Corp. (COSMOS) is a company that sells pharmaceutical products. In the general food, incidental items, pharmaceutical, and cosmetics areas, the company sells a range of commodities. It offers products and services under private brands such ON365, Standard Day, delicious sides, and Antellige EX. Amazon and shop.cosmospc.co.jp are two third-party online marketplaces where the company sells its products. It conducts business through its subsidiaries Green Flash Co., Ltd. and Cosmos Corporation Co., Ltd. Several prefectures, including Nagasaki, Saga, Fukuoka, Yamaguchi, Shimane, Okayama, Hiroshima, Tottori, and Hyogo, are among the prefectures where the company sells its products. Fukuoka City, in the Japanese prefecture of Fukuoka, is home to COSMOS's headquarters.
Key Companies in the submucosal injections market include
-
Seikagaku Corp
-
Ovesco Endoscopy AG
-
GI Supply
-
Cosmo Pharmaceuticals
-
Boston Scientific
-
The Standard
-
Micro-Tech Endoscopy
-
ENDOCLOT PLUS, INC.
Submucosal Injections Market Segmentation
Submucosal Injections Type of Agent Outlook
Submucosal Injections Application Outlook
-
Colorectal Cancer
-
Gastic Cancer
-
Esophageal Cancer
Submucosal Injections End User Outlook
-
Hospitals
-
Surgical Centers
-
Others
 Submucosal Injections Regional Outlook
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
| Report Attribute/Metric |
Details |
| Market Size 2022 |
USD 1.1 Billion |
| Market Size 2023 |
USD 1.16 Billion |
| Market Size 2032 |
USD 1.89 Billion |
| Compound Annual Growth Rate (CAGR) |
6.21% (2023-2032) |
| Base Year |
2022 |
| Market Forecast Period |
2023-2032 |
| Historical Data |
2018- 2022 |
| Market Forecast Units |
Value (USD Billion) |
| Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
Type of Agent, Application, End User, and Region |
| Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered |
The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled |
Seikagaku Corp., Ovesco Endoscopy AG, GI Supply, Cosmo Pharmaceuticals, Boston Scientific, The Standard, Micro-Tech Endoscopy, ENDOCLOT PLUS, INC. |
| Key Market Opportunities |
Patient Preference for Non-Oral Drug Delivery. |
| Key Market Dynamics |
Clinical Efficacy. |
Submucosal Injections Market Highlights:
Frequently Asked Questions (FAQ) :
The submucosal injections market size was valued at USD 1.1 Billion in 2022.
The market is projected to grow at a CAGR of 6.21% during the forecast period, 2023-2032.
North America had the largest share in the market
The key players in the market are Seikagaku Corp., Ovesco Endoscopy AG, GI Supply, Cosmo Pharmaceuticals, Boston Scientific, The Standard, Micro-Tech Endoscopy, ENDOCLOT PLUS, INC.
The Eleview and ORISE gel category dominated the market in 2022.
The Colorectal Cancer had the largest share in the market.
